Cycloxid Mechanism of Action

Pharmacology: Antihemophilic factor: As an inhibitor of plasminogen activation to antifibrin, the potency of this formula is 7 to 8 times superior than the ε-aminocaproic acid in vitro, and 5 to 10 time superior than the ε-aminocaproic acid in vivo, but it contains lesser side effects. The formula not only act to stabilize the fiberization process maintain the blood coagulation function, but can inhibit to sustain blood vessel weakening, platelet mutation or coagulant factor breakdown, to offer blood clotting property against membrane saturation.
Anti-infection & anti-histamine: Bacterial or viral infections or foreign irritants entering the body tend to result in hyperactive blood plasma, which tends to trigger mutative allergic or infectious symptoms as tissue albumins separate from the blood, a phenomenon that can be suppressed by this formula.
Pharmacokinetics: Tranexamic acid is absorbed from the gastrointestinal tract with peak plasma concentrations occurring after about 3 hours. Bioavailability is about 30 to 50%. Tranexamic acid is widely distributed throughout the body and has very low protein binding. It diffuses across the placenta and is distributed into breastmilk. Tranexamic acid has a plasma elimination half-life of about 2 hours. It is excreted in the urine mainly as unchanged drug.